Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05069935 · ClinicalTrials.gov registry record · Phase 1
FT538 in Combination With Monoclonal Antibodies in Advanced Solid Tumors
A Phase 1 study, sponsored by Fate Therapeutics.
- Terminated
- Registry status
- Phase 1
- Development phase
- 16
- Enrollment target
NCT05069935 is a Phase 1 study that was terminated before completion, run by Fate Therapeutics. The registered enrollment target is 16 participants.
The verdict
NCT05069935, a Phase 1 study, was terminated before completion, sponsored by Fate Therapeutics.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 16 participants
- Enrollment target
Study Summary
This is a Phase 1 dose-finding study of FT538 in combination with monoclonal antibodies.
Interventions
- DRUG Cyclophosphamide
- DRUG Fludarabine
- DRUG FT538
- COMBINATION_PRODUCT Monoclonal antibody - Dose Escalation
- COMBINATION_PRODUCT Monoclonal antibody - Dose Expansion
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 16 participants |
| Start Date | 2021-10-15 |
| Est. Completion | 2023-08-11 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05069935
The ClinicalTrials.gov registry entry for NCT05069935 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 16 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Fate Therapeutics, which has 22 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Cyclophosphamide is the first listed.
NCT05069935 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05069935 about?
NCT05069935 is a clinical study titled "FT538 in Combination With Monoclonal Antibodies in Advanced Solid Tumors". This is a Phase 1 dose-finding study of FT538 in combination with monoclonal antibodies.
What is the current status of trial NCT05069935?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 16 participants. The study started on 2021-10-15. Estimated completion is 2023-08-11.
What interventions are being tested in trial NCT05069935?
The interventions under investigation include: Cyclophosphamide (DRUG), Fludarabine (DRUG), FT538 (DRUG), Monoclonal antibody - Dose Escalation (COMBINATION_PRODUCT), Monoclonal antibody - Dose Expansion (COMBINATION_PRODUCT).
Who is sponsoring clinical trial NCT05069935?
This trial is sponsored by Fate Therapeutics, which has 22 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.